Shaanxi Provincial Cancer Hospital Affiliated to Medical School, Xi'an Jiao Tong University, Xi'an, Shaanxi, China (mainland).
Hong Hui Hospital, The Affiliated Hospital, School of Medicine, Xi'an Jiao Tong University, Xi'an, Shaanxi, China (mainland).
Med Sci Monit. 2019 Jan 31;25:888-892. doi: 10.12659/MSM.912320.
MYH9 was first discovered due to thrombocytopenia caused by MYH9 mutation-related abnormalities. In recent years, researchers have increasingly found that MYH9 plays an important role in cancer as a cytokine involved in cytoskeletal reorganization, cellular pseudopodia formation, and migration. MYH9 is closely related to the progress and poor prognosis of most solid tumors, and it is now accepted that MYH9 is a suppressor gene and plays an important role on the re-Rho pathway. Recent research has been limited to the study of tissues. However, it would be more direct and informative to be able to use hematology to assess tumor prognosis and changes in MYH9 levels and NMMHC-IIA. This article summarizes recent research on MYH9 and provides a reference for future clinical research.
MYH9 最初是由于 MYH9 突变相关异常导致的血小板减少而被发现的。近年来，研究人员越来越发现 MYH9 作为一种参与细胞骨架重排、细胞伪足形成和迁移的细胞因子，在癌症中起着重要作用。MYH9 与大多数实体瘤的进展和不良预后密切相关，现在人们认为 MYH9 是一个抑癌基因，在再 Rho 途径中发挥着重要作用。最近的研究仅限于组织研究。然而，能够利用血液学来评估肿瘤的预后以及 MYH9 水平和 NMMHC-IIA 的变化将更加直接和有信息。本文总结了 MYH9 的最新研究成果，为未来的临床研究提供了参考。
